Pfizer Inc PFE

$29.44 +0.23 (0.79%)

Valuation

Market cap
161,699,744,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.31
Forward PE
9.61
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
30,041,087
Avg volume
34,042,121
Day's range
$29.42 – $29.88
Shares out
5,699,674,000
Stochastic %K
88%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

zaza1 Oct 15, 6:58 PM
$OPK $PFE With its lab business sold, OPKO is now a highly attractive acquisition target for Pfizer. OPKO comes to the table as a leaner company with a massive cash pile, the partnered growth hormone, promising R&D tech, and a huge ModeX partnership with Merck. This unique combination of assets makes a buyout make more strategic sense now than ever..
0 replies
TradingLive Oct 15, 6:28 PM
$PFE This needs to be in 30's ...been years!
0 replies
reyofhope Oct 15, 5:27 PM
$PFE if it's a democratic sweep then this guy below lands in Washington DC.
1 replies
dixiebull Oct 15, 4:53 PM
$PFE woul dot have been my choice I prefer $MRNA
0 replies
mimiwor Oct 15, 4:50 PM
$OPK Look at it...they have many pipeline partnering with $PFE and already have commercialized product...
0 replies
Jefftennis36 Oct 15, 4:42 PM
$PFE :0
0 replies
OneBrightDay Oct 15, 4:29 PM
$PFE struggling to breach 30s.. big pull back or pish through and set a new floor 💡💡💡
0 replies
pineconecameo Oct 15, 4:22 PM
$PFE paciencia
1 replies